The dual-specificity kinase DYRK1A modulates the levels of cyclin L2 to control HIV replication in macrophages by Kisaka, Javan K et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2-28-2020 
The dual-specificity kinase DYRK1A modulates the levels of cyclin 
L2 to control HIV replication in macrophages 
Javan K. Kisaka 
Lee Ratner 
George B. Kyei 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
The Dual-Specificity Kinase DYRK1A Modulates the Levels of
Cyclin L2 To Control HIV Replication in Macrophages
Javan K. Kisaka,a Lee Ratner,a,b George B. Kyeia,b,c
aDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
bDepartment of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
cDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana
ABSTRACT HIV replication in macrophages contributes to the latent viral reservoirs,
which are considered the main barrier to HIV eradication. Few cellular factors that
facilitate HIV replication in latently infected cells are known. We previously identified
cyclin L2 as a critical factor required by HIV-1 and found that depletion of cyclin L2
attenuates HIV-1 replication in macrophages. Here we demonstrate that cyclin L2
promotes HIV-1 replication through interactions with the dual-specificity tyrosine
phosphorylation-regulated kinase 1A (DYRK1A). Cyclin L2 and DYRK1A were colocal-
ized in the nucleus and were found together in immunoprecipitation experiments.
Knockdown or inhibition of DYRK1A increased HIV-1 replication in macrophages,
while depletion of cyclin L2 decreased HIV-1 replication. Furthermore, depletion of
DYRK1A increased expression levels of cyclin L2. DYRK1A is a proline-directed kinase
that phosphorylates cyclin L2 at serine residues. Mutations of cyclin L2 at serine resi-
dues preceding proline significantly stabilized cyclin L2 and increased HIV-1 replica-
tion in macrophages. Thus, we propose that DYRK1A controls cyclin L2 expression,
leading to restriction of HIV replication in macrophages.
IMPORTANCE HIV continues to be a major public health problem worldwide, with
over 36 million people living with the virus. Although antiretroviral therapy (ART)
can control the virus, it does not provide cure. The virus hides in the genomes of
long-lived cells, such as resting CD4 T cells and differentiated macrophages. To get
a cure for HIV, it is important to identify and characterize the cellular factors that
control HIV multiplication in these reservoir cells. Previous work showed that cyclin
L2 is required for HIV replication in macrophages. However, how cyclin L2 is regu-
lated in macrophages is unknown. Here we show that the protein DYRK1A interacts
with and phosphorylates cyclin L2. Phosphorylation makes cyclin L2 amenable to
cellular degradation, leading to restriction of HIV replication in macrophages.
KEYWORDS DYRK1A, cyclin L2, human immunodeficiency virus, macrophages,
protein phosphorylation
Infection with human immunodeficiency virus (HIV) continues to be a public healthchallenge, with over 1.2 million deaths annually (1). Although antiretroviral therapy
(ART) can suppress the virus and reduces mortality, it does not provide cure (2, 3). The
main obstacle to an HIV cure is persistence of the provirus in latently infected quiescent
cells, such as resting CD4 T cells (4–8). HIV latency may be established through
infection of actively dividing cells that revert to a resting state (9, 10) or direct infection
of resting CD4 T cells (11, 12). Other potential reservoirs include macrophages and
microglia in the central nervous system (13–16). Although the contribution of macro-
phages to the HIV reservoir is still debated, accumulating evidence suggests that they
could play an important role (17). First, the discovery of long-lived yolk sac-derived
tissue resident macrophages capable of self-renewal provides a new paradigm for
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viewing macrophages as potential reservoirs. Second, Honeycutt et al. have shown in
a macrophage-only mouse model that a form of latency and reactivation after ART
interruption is feasible (18). Third, some virologically suppressed macaques on ART can
express simian immunodeficiency virus (SIV) in brain macrophages when treated with
latency-reversing agents (19). Fourth, resident macrophages in the urethras of patients
suppressed on ART have integrated HIV DNA, can produce RNA, and can be reactivated
to make replication-competent virus (20). Identification and targeting of cellular factors
that control HIV-1 replication in quiescent cells constitute an important intervention
strategy toward HIV-1 eradication. Therefore, there is a need to identify more cellular
factors that control HIV replication, transcription, and reactivation in macrophages.
A group of proteins that are becoming increasingly important in the HIV life cycle
are cyclins and their counterparts cyclin-dependent kinases (CDKs). Cyclins are proteins
that regulate the cell cycle. They are synthesized during interphase and rapidly de-
graded at each mitotic phase (21, 22). They bind to and activate specific CDKs which,
in turn, control cell division and transcription (23–25). Cyclins determine the activity,
cellular localization, substrate specificity, and stability of the CDK (22, 26). Several
cyclins have been shown to play a role in different parts of the HIV life cycle. The most
important and well-characterized of these is cyclin T1/CDK9 (P-TEFb), a complex
required for HIV transcription through interaction with Tat (27). In macrophages, as in
resting T cells, the levels of cyclin T are reduced, and this may play a role in latency (27).
Recently, CDK11, which partners with cyclin L, was shown to regulate HIV 3= mRNA
processing. Cyclin L interacts with CDK11, which phosphorylates the carboxyl-terminal
domain (CTD) of polymerase II (Pol II) and splicing factor SC35. Phosphorylation of the
CTD is required for transcription initiation, elongation, and RNA processing (28–31). The
cyclin L family includes cyclins L1 and L2. Cyclin L1 has three isoforms, L1, L1, and
L1, whereas cyclin L2 has two isoforms, L2 and L2 (32, 33). Loyer et al. determined
that both cyclins L1 and L2 are ubiquitously expressed in human cell lines and mouse
tissues and that both interact with essential splicing factors (33).
Using a yeast two-hybrid screen, we previously identified cyclin L2 as a critical factor
required for HIV replication in noncycling cells, such as differentiated THP-1 cells and
monocyte-derived macrophages (MDMs), but not in dividing cells (34). Cyclin L2 binds
to and induces degradation of HIV-1 restriction factor sterile alpha motif and HD
domain-containing protein 1 (SAMHD1) by recruiting cellular factors DCAF1, Cul4, and
DDB1 to the proteasome. The depletion of cyclin L2 abrogates SAMHD1 degradation and
decreases HIV-1 replication in macrophages (34). Cyclin L2 has an N-terminal RNA-binding
domain (the “cyclin box”) common for all cyclins and a C-terminal arginine- and serine-rich
(RS) domain present only in the cyclin L proteins (35). The RS domain-containing proteins
are essential splicing factors that are associated with the spliceosome (36). The RS domain
is rich in dipeptide repeats of arginine and serine residues (30). It enables the cyclins to
localize to nuclear speckles (37, 38), where they are thought to be involved in pre-mRNA
processing (33, 37, 39).
Cyclin L2 is phosphorylated by the dual-specificity tyrosine phosphorylation-
regulated kinase 1A (DYRK1A) (39). DYRK1A belongs to the DYRK family of protein
kinases (40). In mammals, there are five subclasses (DYRK1A, DYKRK1B, DYRK2, DYRK3,
and DYRK4) (40, 41). They share a conserved catalytic domain, but only DYRK1A has a
C-terminal domain rich in serine and threonine residues. DYRK1A is expressed in the
nucleus (42, 43) and the cytosol (41, 44). In the nucleus, it is localized in the nuclear
speckles, suspected to be splicing factor compartments (43, 45). DYRK1A has been
associated with many cellular processes, such as brain development, T cell differenti-
ation, and pancreatic islet cell formation (41, 46, 47). de Graaf and colleagues identified
DYRK1A as a putative kinase for cyclin L2. Overexpression of DYRK1A in COS-7 cells
increased the phosphorylation of cyclin L2 (39). Since most cyclins are controlled by
phosphorylation (23), we postulated that the effect of cyclin L2 on HIV may be
regulated through interactions with DYRK1A. Here we show that cyclin L2 interacts with
DYRK1A in cycling and noncycling cells. Knockdown or pharmacological inhibition of
DYRK1A resulted in a severalfold increase in HIV replication in nondividing cells but had
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minimal effect in dividing cells. This increase in HIV replication upon DYRK1A inhibition
is dependent on intact cyclin L2. We found that depletion of DYRK1A increases cyclin
L2 levels, thus increasing HIV replication. We present evidence to show that DYRK1A
enhances the degradation of cyclin L2 through phosphorylation to restrict HIV repli-
cation in macrophages.
RESULTS
Cyclin L2 interacts with DYRKIA through its RS domain. To determine whether
cyclin L2 interacts with DYRK1A, we transfected HeLa cells with green fluorescent
protein (GFP)-DYRK1A and immunostained for endogenous cyclin L2. As shown in Fig.
1A, most of the cyclin L2 in the nucleus colocalized with DYRK1A in nuclear speckles
(39). We confirmed these findings in macrophage-like cells by performing coimmuno-
precipitations for the two endogenous proteins in differentiated THP-1 cells. Figure 1B
shows that cyclin L2 coimmunoprecipitated with DYRK1A in cells transfected with
control small interfering RNA (siRNA) but not in DYRK1A knockdown cells or IgG
controls. These results show that the two proteins specifically interact. Next, we
determined which domain of cyclin L2 is responsible for the interaction. Cyclin L2 has
two main domains, the cyclin box in the N terminus and an arginine- and serine-rich
(RS) domain in the C terminus (Fig. 1C). To find which domain is critical for interacting
with DYRK1A, we constructed three Myc-tagged clones consisting of the full-length
cyclin L2, cyclin L2ΔRS (residues 1 to 286), and cyclin L2Δc-box (residues 287 to 520).
We transfected 293T cells with these constructs, pulled down Myc with a monoclonal
antibody, and immunoblotted for endogenous DYRK1A. Full-length cyclin L2 interacted
with DYRK1A, as expected (Fig. 1D). In addition, the mutant containing the RS domain
(cyclin L2Δc-box) coimmunoprecipitated with DYRK1A. However, the mutant lacking
the RS domain (cyclin L2ΔRS) could not pull down DYRK1A, indicating that the RS
domain is required for the interaction between the two proteins.
FIG 1 Cyclin L2 interacts with DYRK1A through the RS domain. (A) Cyclin L2 colocalizes with DYRK1A in the nucleus. HeLa cells were transfected with
GFP-DYRK1A and immunostained for endogenous cyclin L2 (red). Cell A is enlarged to highlight colocalization. Arrows show areas of colocalization. Percent
colocalization is shown by Pearson correlation. (B) Endogenous cyclin L2 coimmuniprecipitates with DYRK1A. Cyclin L2 antibody or IgG was used to
immunoprecipitate the protein in differentiated THP-1 cells transfected with control or DYRK1A siRNA and immunoblotted for the endogenous proteins. (C)
Schematic of the cyclin L2 constructs used for experiments whose results are shown in panel D. (D) The RS domain of cyclin L2 is required for interaction with
DYRK1A. 293T cells were transfected with the indicated Myc-tagged cyclin L2 constructs in panel C and immunoprecipitation was performed with monoclonal
Myc antibody. Western blots were probed for Myc or endogenous DYRK1A. Blots are representative of results from two or three independent experiments.
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Knockdown of DYRK1A disproportionately increases HIV replication in nondi-
viding cells. In dividing cells, previous work showed that depletion of DYRK1A results
in less than a 2-fold increase in HIV replication (48). Given that the action of cyclin L2
on HIV replication is restricted to macrophages and the two proteins interact, we
wondered what effect DYRK1A would have on HIV replication in nondividing cells.
Therefore, we knocked down DYRK1A in HeLa and THP-1 monocytic cells to compare
degrees of HIV replication in the two cell types (Fig. 2A). As previously reported (48),
there was about a 1.5-fold increase in HIV infection in HeLa cells (Fig. 2B). To test the
idea that DYRK1A may be more important for HIV replication in monocytes/macro-
phages, we used stable THP-1 cells carrying either control or DYRK1A small hairpin RNA
(shRNA). Since THP-1 cells can be differentiated into macrophage-like cells with phorbol
12-myristate 13-acetate (PMA), they provide a good model to compare the roles of
DYRK1A in HIV infection in dividing and nondividing cells. Knockdown of DYRK1A with
shRNA in undifferentiated THP-1 monocytes resulted in about a 3-fold increase in HIV
infection (Fig. 2C). However, when the THP-1 cells were differentiated (dTHP-1) before
infection, HIV replication increased to 8-fold (Fig. 2D). To confirm these results, we used
siRNA to knock down DYRK1A in primary monocyte-derived macrophages (MDMs)
isolated from three different HIV-negative donors (Fig. 2E). As shown in Fig. 2F to H, in
DYRK1A knockdown cells, HIV infection increased 9.7- to 12.7-fold depending on the
donor. The increases in HIV replication were not due to proliferation of THP-1 cells or
MDMs, as shown by the cell proliferation assays whose results are shown in Fig. 2I to
FIG 2 Knockdown of DYRK1A disproportionately increases HIV replication in nondividing cells. (A) Western blot showing the knockdown of
DYRK1A in HeLa, THP-1, and differentiated THP-1 (dTHP-1) cells. Cell lysates taken at 48 h prior to viral infections are shown for each cell type.
(B) HeLa cells were transfected with control or DYRK1A siRNA for 48 h and infected with VSV-G-pseudotyped HIV-1Luc for 48 h. (C and D) Stable
THP-1 cells expressing control or DYRK1A shRNA were either directly infected with HIVLuc or differentiated into macrophages and then infected
with HIVLuc for 48 h. HIV infection was measured by luciferase luminescence in cell lysates normalized to total protein concentration. (E)
Knockdown DYRK1A in monocyte-derived macrophages (MDMs) isolated from HIV-negative donors after 48 h of siRNA transfection. (F to H) MDMs
from three different donors were infected with VSV-G-pseudotyped HIV-1Luc for 48 h and HIV infection was measured as described above. (I and
J) Differentiated THP-1 cells with control of DYRK1A shRNA were infected with HIV-1 for 48 h and the MTT assay was performed as described in
Materials and Methods. (K) MDMs with control or DYRK1A siRNA were infected with HIV-1 for 48 h and the MTT assay was performed. Data are
means, and error bars indicate SEM (n  3). **, P  0.001; *, P  0.05, Student’s t test.
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K. Next, we used macrophage-tropic replication-competent HIV-1 (BaL-3) to determine
if DYRK1A would have the same effect with multiple rounds of infection. We infected
control or DYRK1A knockdown MDMs isolated from three different donors (Fig. 3A) with
HIV-1 BaL-3 for a total of 72 h. After 24 h of infection, we replaced the media and
collected supernatants after 48 h. We then used the collected virus to infect TZM-bl
indicator cells. As shown in Fig. 3B to D, knockdown of DYRK1A increased replication
of HIV-1 8- to 10-fold depending on the donor. Cell lysates from the MDMs were
processed for Western blotting and showed a significant increase in HIV Gag proteins
in DYRK1A knockdown cells (Fig. 3E). Finally, we employed INDY, an established
inhibitor of DYRK1A which binds to the protein’s ATP pocket to inhibit its action (49).
Treatment with INDY increased HIV replication in a dose-dependent manner in all three
donors (Fig. 3F to H). Treatment with INDY did not result in proliferation of MDMs (Fig.
3H). Taken together, these results confirm that DYRK1A has a more pronounced effect
on HIV replication in macrophages.
Depletion of cyclin L2 abolishes DYRK1A-mediated HIV restriction. Since cyclin
L2 promotes HIV replication in macrophages and DYRK1A has the opposite effect, we
investigated whether the DYRK1A restriction of HIV replication in macrophages is
dependent on intact cyclin L2. If that were the case, depletion of cyclin L2 would
abolish the effect of DYRK1A illustrated in Fig. 2 and 3. Consistent with the DYRK1A
knockdown results, treatment of differentiated THP-1 cells with INDY increased HIV
infection up to 10-fold (Fig. 4A), compared to only 2-fold in undifferentiated cells (Fig.
4B). To show that INDY worked through DYRK1A, we repeated the experiments with
MDMs from three donors. When INDY (50 M) was added to the MDMs with DYRK1A
knockdown, no further increase in HIV replication was observed, indicating that the
FIG 3 Knockdown or pharmacological inhibition of DYRK1A increases HIV replication in multiple rounds of
infection. (A) Western blots showing DYRK1A knockdown in three HIV-negative donors. (B to D) MDMs with control
of DYRK1A siRNA were infected with macrophage-tropic replication-competent HIV-1 (BaL-3) for 6 h and washed,
and medium was replaced after 48 h. Viral particles were collected after 72 h and used to transduce TZM-bl
indicator cells. Luciferase luminescence in cell lysates was used as a measure of HIV replication. (E) Cell lysates from
the respective MDMs were used for Western blots for HIV-1 Gag and actin. (F to H) MDMs were infected with HIV-1
BaL-3 for 72 h in the presence of INDY or dimethyl sulfoxide (DMSO). HIV replication was measured as for panels
B to D. (I) MDMs were treated with INDY and infected with HIV-1 for 48 h, and the MTT assay was performed as
described in Materials and Methods. Data are means, and error bars indicate SEM (n  3). *, P  0.01; **, P  0.0001
(Student’s t test).
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effect of INDY on HIV replication was likely mediated through DYRK1A (Fig. 4C to E).
Next, we used cyclin L2 CRISPR/Cas9 knockout THP-1 cells to interrogate the effect of
DYRK1A inhibition in the context of cyclin L2 depletion. In control parental cells,
treatment with INDY increased HIV infection 8-fold. However, in cyclin L2 knockout
cells, the effect of INDY was reduced only 0.8-fold (Fig. 4F and G), without a decrease
in cell numbers (Fig. 4H). This shows that the interaction between the two proteins has
functional consequences on HIV replication and that intact cyclin L2 is required for the
effect of DYRK1A on HIV replication.
DYRK1A controls cyclin L2 levels in macrophages. Next we proceeded to deter-
mine a possible mechanism for how cyclin L2-DYRK1A interactions control HIV repli-
cation in macrophages. Since DYRK1A is a kinase for cyclin L2 and multiple kinases
modulate the levels of their respective cyclins (50, 51), we wondered if DYRK1A controls
cyclin L2 levels in macrophages. For instance, if DYRK1A reduced the levels of cyclin L2
in macrophages, that could reduce the amount of HIV produced in those cells. First, we
immunoblotted for levels of the two proteins in dividing and nondividing THP-1 cells.
As shown in Fig. 5A and B, while the levels of DYRK1A were higher in differentiated
THP-1 cells, cyclin L2 levels were 2.5-fold lower in the same cells. When the cells were
treated with the proteasome inhibitor MG132, the levels of cyclin L2 in dTHP-1 cells
were restored to the levels detected in dividing cells. This suggests that increased
expression of DYRK1A in nondividing cells accelerates degradation of cyclin L2 through
the proteasome. To determine a direct role for DYRK1A in modulating cyclin L2 levels,
we immunoblotted for cyclin L2 in control versus DYRK1A knockdown differentiated
THP-1 cells. Figure 5C shows that compared to those in controls, cyclin L2 levels
increased 2-fold in cells with DYRK1A depletion. Next, we immunoprecipitated cyclin L2
in dTHP-1 cells treated with control or DYRK1A siRNA and immunoblotted for total
cyclin L2 or phosphorylated cyclin L2. While total cyclin L2 was increased, the phos-
phorylated portion was reduced, as expected (Fig. 5D and E). In addition, total SAMHD1
levels were reduced but phosphorylated levels remained the same, consistent with our
previous findings that increased cyclin L2 reduces SAMHD1 levels but has no effect on
the phosphorylated portion (34). Finally, we overexpressed increasing amounts of
DYRK1A to determine the effect on cyclin L2 levels. Increasing levels of DYRK1A
resulted in proportional degradation of cyclin L2 (Fig. 5F and G). When MG132 was
added where DYRK1A had the most effect, cyclin L2 degradation was rescued. Taken
together, these data show that DYRK1A increases the turnover of cyclin L2 through the
proteasome, resulting in reduced HIV production.
FIG 4 Depletion of cyclin L2 abolishes DYRK1A-mediated HIV restriction. (A) Differentiated THP-1 cells were infected with VSV-G-pseudotyped HIV-1Luc for 48
h in the presence of DMSO or increasing concentrations of INDY. Luciferase luminescence in cell lysates was used as a measure of HIV infection. (B)
Undifferentiated THP-1 cells were infected with VSG-G-pseudotyped HIV-1Luc for 48 h with or without INDY. HIV infection was measured as described above.
(C to E) Monocyte-derived macrophages were transfected with control or DYRK1A siRNA for 48 h. Cells were infected with VSV-G-pseudotyped HIV-1Luc for
48 h and HIV infection was measured as described above. (F) Western blot showing cyclin L2 CRISPR/Cas9 knockout in differentiated THP-1 cells. (G) Cyclin L2
CRISPR/Cas9 knockout differentiated THP-1 cells or parental controls were infected with HIV-1Luc with or without INDY for 48 h. HIV nonnucleoside reverse
transcriptase inhibitor zidovudine (AZT; 20 M) was used as a positive control. (H) Parental or cyclin L2 knockout THP-1 cells were infected with HIV-1 for 48
h and the MTT assay was performed. Data are means, and error bars indicate SEM (n  3). *, P  0.001; **, P  0.0001 (Student’s t test).
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Cyclin L2 is stabilized by dephosphorylation to increase HIV replication. To test
the possibility that DYRK1A-mediated phosphorylation increases cyclin L2 degradation,
we mutated serine residues in cyclin L2 shown previously to be phosphorylated by
DYRK1A (39). We made phospho mutants of cyclin L2 by replacing serine residues that
are adjacent to proline with alanine in the RS domain at the C terminus. For mutant 1,
named P-369, four serine residues were mutated to alanine: S330, S338, S348, and S369.
For mutant 2, named P-330, seven serine residues were mutated to alanine: S330, S338,
S348, S369, S394, S401, and S427.
First, we expressed the wild type (WT) and mutants together with DYRK1A in 293T
cells and immunoblotted for phosphorylated and total cyclin L2. As shown in Fig. 6A,
while the total levels of the mutants were increased compared to those of WT cyclin L2,
the phosphorylated portions were reduced, as expected. This indicated that the
dephosphorylated cyclin L2 mutants may be more stable than the WT. To determine
the stability of the WT and mutants in a more methodical manner, we treated cells with
cycloheximide to block new protein synthesis and performed a chase for 36 h to
generate degradation curves. The results showed that the mutant with the most
mutated DYRK1A phosphorylation sites (P-330) was the slowest to degrade (Fig. 6B and
C). This shows that phosphorylation of cyclin L2 by DYRK1A increased cyclin L2
FIG 5 Knockdown of DYRK1A increases levels of cyclin L2, while overexpression of DYRK1A reduces cyclin L2 levels. (A) Western blot showing levels of
endogenous cyclin L2 and DYRK1A in THP-1 and differentiated THP-1 cells with and without the proteasome inhibitor MG132. Results represent those from
three independent experiments. Levels of cyclin L2 normalized to actin are shown below the blot. (B) Quantitation of cyclin L2 expression levels in dividing
and nondividing THP-1 cells. (C) Differentiated THP-1 cells were transfected with control or DYRK1A siRNA, and levels of cyclin L2 and DYRK1A were measured
by Western blotting. The experiment was repeated three times, and cyclin L2 actin ratios are shown below the blot. (D and E) Differentiated THP-1 cells were
transfected with control or DYRK1A siRNA and Western blotting was performed for the indicated proteins in the cell lysates. A phosphoserine antibody was
used to detect phosphorylated cyclin L2 (P-serine) after immunoprecipitation. Quantification of total cyclin L2 and phosphorylated portion relative to actin from
three experiments is shown in panel E. (F and G) Myc-DYRK1A was expressed in increasing plasmid concentrations in 293T cells for 24 h with and without
MG132. Levels of endogenous cyclin L2 were detected by Western blotting and quantified for three independent experiments (G). Data are means, and error
bars indicate SEM (n  3). *, P  0.05; **, P  0.001; ***, P  0.0001; , P  0.05.
FIG 6 Mutation of DYRK1A phosphorylation sites increases cyclin L2 stability and HIV replication in differentiated THP-1 cells. (A) Phosphorylation of cyclin L2
decreases with increasing numbers of serine-to-alanine mutants. 293T cells were cotransfected with plasmids expressing GFP-DYRK1A and Myc-cyclin L2
mutants (cyclin L2 WT, cyclin L2 P369, and cyclin L2 P330; see text for details) for 48 h. Cells were lysed and immunoblotted with DYRK1A antibody, P-serine,
and Myc. (B and C) Cyclin L2 stability is increased by phosphorylation site mutations. Cells expressing WT and mutant cyclin L2 were treated with cycloheximide
to block new protein synthesis. Cells were lysed at the indicated time points and Western blotting was performed for Myc-cyclin L2 and actin. Quantification
of cyclin L2/actin ratios was used to generate degradation curves from three independent experiments (C). (D) Myc-tagged mutant and wild-type cyclin L2 were
expressed in cyclin L2 CRISPR/Cas9 knockout THP-1 cells, differentiated with PMA, and infected with HIV-1Luc. HIV infection was measured as indicated
previously. (E) Expression of Myc-cyclin L2 WT and mutants in dTHP-1 cells used for panel D. Data are means, and error bars indicate SEM (n  3). ***, P  0.001,
ANOVA.
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degradation. Next, we tested if the mutants were functional and whether they affected
HIV-1 replication. We expressed the Myc-tagged mutants in cyclin L2 CRISPR/Cas9
knockout THP-1 cells, differentiated with PMA and infected with HIV-1 Luc. As shown
in Fig. 6D, wild-type cyclin L2 retained its function in THP-1 cells. We observed a 5-fold
increase in HIV replication in cells expressing wild-type cyclin L2 and up to a 7.5-fold
increase in cells expressing cyclin L2 (P-330), the mutant with the most dephosphor-
ylation. This suggests that the more stable cyclin L2 in macrophages, the higher the HIV
replication.
DYRK1A inhibition increases HIV-1 transcription. To determine which step of the
viral life cycle is modulated by the cyclin L2-DYRK1A interaction, we performed exper-
iments to evaluate late reverse transcription (RT) and transcription of HIV provirus. We
infected MDMs and dTHP-1 cells with HIV-1 BaL-3 and quantified the levels of HIV-1
DNA by quantitative PCR (qPCR) 48 h postinfection to determine whether DYRK1A
knockdown had any effect on late reverse transcription. As shown in Fig. 7A to C, the
levels of HIV-1 gag DNA were unchanged, suggesting that knockdown of DYRK1A did
not alter reverse transcription in either MDMs or differentiated THP-1 cells. Next, to
determine HIV mRNA expression from integrated HIV provirus, we infected differenti-
ated THP-1 cells with full-length HIV-1 for 24 h, washed and treated with integrase
inhibitor raltegravir and protease inhibitor darunavir to prevent new integration and
reinfection, respectively. After 24 h of INDY treatment, we isolated RNA from the cells
and measured gag mRNA as a measure of HIV transcription. We observed a 3-fold
increase in gag mRNA upon DYRK1A knockdown (Fig. 7D) or inhibition with INDY (Fig.
7E). Finally, to confirm that this effect on transcription was through cyclin L2, we used
cyclin L2/CRISPR/Cas9 knockout cells. As shown in Fig. 7F, knockout of cyclin L2
abrogated the increase in transcription observed with DYRK1A knockdown. Taken
together, these data show the requirement for cyclin L2 for DYRK1A actions on HIV-1
replication in macrophages.
DISCUSSION
Identification of cellular factors involved in HIV-host interactions is critical to under-
standing mechanisms of persistence and latency, which could eventually lead to cure.
Here we show that cyclin L2, previously shown to degrade SAMHD1, interacts with the
kinase DYRK1A. Knockdown or pharmacological inhibition of DYRK1A had pronounced
effects on HIV replication in macrophages compared to dividing cells, even with
FIG 7 Inhibition of DYRK1A increases HIV-1 transcription. (A) Western blots showing knockdown of DYRK1A in MDMs and differentiated THP-1 cells. (B and C)
MDMs or dTHP-1 cells were infected with HIV-1Luc for 24 h. To measure late reverse transcription, quantification of HIV DNA was done by qPCR. (D)
Differentiated THP-1 cells with control or DYRK1A shRNA were infected with full-length HIV-1 for 24 h, washed, and incubated with raltegravir and darunavir
for another 24 h. Total cell RNA was isolated and reverse transcription-quantitative PCR (qRT-PCR) was performed for gag mRNA as a measure of HIV
transcription. (E) Differentiated THP-1 cells treated with DMSO or INDY were infected as for panel D and gag mRNA was quantified. (F) Cyclin L2 CRISPR/Cas9
knockout or parental control differentiated THP-1 cells were infected as for panel D and gag mRNA was quantified. Data are means, and error bars indicate SEM
(n  3). **, P  0.0001; , P  0.05, unpaired Student’s t test.
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multiple rounds of infection. Overall, the data point to a mechanism whereby inhibition
of DYRK1A results in increased amounts and a more stable cyclin L2 which conse-
quently promote HIV replication in macrophages. Since cells with knockdown of both
proteins produce little HIV, it is likely that cyclin L2 plays the central role in this
interaction. Degradation of a cyclin by DYRK1A is not without precedent. Thompson et
al. showed that DYRK1A phosphorylates cyclin D3 to promote its degradation and
enhance quiescence in T and B cells (52). Degradation of cyclin L2 leads to restriction
of HIV infection in macrophages but less so in dividing cells. The reason for the
pronounced effect in nondividing cells is still unclear. Given that SAMHD1 phosphor-
ylation makes it inactive in dividing cells (53, 54), it is possible that differential
phosphorylation in dividing versus nondividing cells could be the ultimate mechanism.
Here, in the context of a clean background (cyclin L2 knockout cells), we show that
expression of cyclin L2 in macrophages increases HIV replication, confirming our
previous results (34). We found that terminally differentiated cells express more
DYRK1A, and less cyclin L2, which correlates with the production of less HIV. It will be
interesting to determine how the interplay between the two proteins affects HIV
replication in resting T cells, which are considered differentiated and critical for HIV
latency. Supporting the assertion that cyclin L2/DYRK1A interactions may be critical in
HIV latency are the findings that inhibitors of DYRK1A increase HIV latency reversal in
resting T cells (55). Although the mechanism for this finding is not known, it will not be
surprising if cyclin L2 plays a role in resting T cells similar to the one it plays in
macrophages.
A unique feature of the cyclin L proteins is possession of the RS domain, a hallmark
of splicing factors (33, 37, 39, 56). Cyclin L2 interacts with splicing factors and is believed
to be involved in pre-mRNA splicing. Interestingly, we found that the RS domain is
required for interactions with DYRK1A, making it likely that DYRK1A also localizes in
splicing factor compartments. We found that knockdown of DYRK1A resulted in
increased HIV mRNA production from integrated provirus. This could be at the level of
transcription or splicing. Since knockdown of cyclin L2 abrogated this effect, it would
suggest that cyclin L2 plays a role in HIV transcription or splicing in macrophages.
Recent findings that SAMHD1 plays a role in HIV transcription in resting cells (57) make
this an interesting line of investigation for future studies. Previous studies showed that
DYRK1A inhibits HIV transcription in actively dividing cells through nuclear factor of
activated T cells (NFAT) (48). However, how HIV transcription or splicing in macro-
phages is controlled by cyclin L2, DYRK1A, and NFAT interplay remains to be deter-
mined.
We found that cyclin L2 is degraded through the proteasome and that this degra-
dation was dependent on DYRK1A. Knockdown of DYRK1A or mutations of its phos-
phorylation sites in cyclin L2 had the same effect of stabilizing cyclin L2 and increasing
HIV replication in macrophages. In this regard, cyclin L2 resembles cyclin D1 and cyclin
E, which are also stabilized upon dephosphorylation (50, 51). Given that cyclin L2 has
multiple potential phosphorylation sites, especially in the RS domain, it is likely that
other kinases or phosphorylation sites play a role in its phosphorylation in macro-
phages. This could explain the moderate increases in HIV replication when the phospho
mutants were expressed in macrophages compared to the wild type.
Our previous studies showed cyclin L2-mediated degradation of SAMHD1 resulted
in fewer HIV reverse transcription products. In this study, DYRK1A did not affect HIV
reverse transcripts but knockdown increased HIV mRNA production. Therefore, it is
possible that cyclin L2 affects the HIV life cycle at two distinct points depending on the
specific interacting protein partner.
From the foregoing, a model emerges whereby cyclin L2 control of HIV replication
in macrophages is modulated in part by the kinase DYRK1A. Interaction between the
two proteins keeps the levels of cyclin L2 to a minimum, a situation that favors HIV
restriction in macrophages. We conclude that regulation of cyclin L2 levels by DYRK1A
contributes to HIV restriction in macrophages.
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Cell culture, reagents, and antibodies. HeLa, 293T, and TZM-bl cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), antibiotic-
antimycotic, glutamine, and sodium pyruvate. THP-1 cells were maintained in RPMI medium supple-
mented with L-glutamine and 10% FBS, antibiotic-antimycotic, and sodium pyruvate. Where indicated,
50 ng/ml of phorbol 12-myristate 13-acetate (PMA) was used to differentiate THP-1 into macrophages for
48 h. HeLa, THP-1, and 293T cells were obtained from the ATCC. TZM-bl cells were obtained from the NIH
AIDS Reagent Program, Division of AIDS, NIAID. Human monocyte-derived macrophages (MDMs) were
prepared from HIV-1-negative donors using Ficoll-Hypaque density gradient centrifugation (GE Health-
care). Isolated monocytes were maintained in RPMI medium supplemented with 10% FBS and then
differentiated with 50 ng/ml of macrophage colony-stimulating factor (M-CSF) for 7 days prior to
transfection. Cyclin L2 CRISPR/Cas9 knockout in THP-1 cells was performed in collaboration with the
Genome Engineering and iPSC Center (GEiC) at Washington University, targeting exons 2 and 6. The
sequences of the guide RNA pairs were as follows: for exon 2, ACTTGGTATAAAAGAACCGCNGG and
GTCCTTCGTGAAGCACTCCANGG, and for exon 6, CTTTGCCCAATCGTCCCCATNGG and AATGGGGACGAT
TGGGCAAANGG. The resulting cell line had no expression of cyclin L2 protein (see figures). HIV
replication could be rescued with expression of cyclin L2 in these cells. Knockout THP-1 cells were
maintained in RPMI medium as described above.
The 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay reagents were obtained
from Roche, and cell proliferation assays were performed according to the manufacturer’s protocol and
as described previously (58). In these assays, MTT dye is reduced to formazan by mitochondrial enzymes
from viable cells. Absorbance reading increases with cellular proliferation.
Goat polyclonal cyclin L2 and goat polyclonal actin primary antibodies were purchased from Santa
Cruz Biotechnologies. Rabbit cyclin L2 polyclonal antibody was purchased from Novus Biological
(number NB100-87009) and ProSci Inc. (number 8005). Myc antibody was obtained from Clontech.
Donkey anti-goat secondary antibody was obtained from Santa Cruz Biotechnologies. Goat anti-mouse
and goat anti-rabbit antibodies were purchased from Invitrogen. DYRK1A antibody was from Abnova
(H00001859-M01).
Plasmid, siRNA, and shRNA transfections. Full-length Myc-cyclin L2 was purchased from Origene
(RC213824). This was used as a template to make constructs of cyclin L2 by standard PCR and cloning
methods. To express wild-type and mutant cyclin L2 in THP-1, full-length cyclin L2 (cyclin L2 WT), cyclin
L2 P369 (S330A, S338A, S348A, and S369A), and cyclin L2 P330 (S330A, S338A, S348A, S369A, S394A,
S401A, and S427A) were cloned into doxycycline-inducible lentiviral vector TtRMPVIR, which was a gift
from Scott Lowe (Addgene; plasmid number 27995) (59). Mutants for cyclin L2 were made in wild-type
cyclin L2 in pCMV6-Entry vector (Origene; RC213824) and cloned into TtRMPVIR vector (Addgene; 27995)
using standard mutagenesis, PCR, and cloning methods.
A pool of four siRNAs (SMARTpool) for DYRK1A was obtained from Dharmacon (GE Healtcare; catalog
number L-004805-00-0005). shRNAs for DYRK1A were obtained from the Washington University Genome
Center. A cocktail of three shRNAs with sequences CCAGCAGTTGATTCTTGTATT, GCTGCTAATACCTTGGA
CTTT, and CAGTATATTCAGAGTCGCTTT was used. The HIV-1 luc Δenv reporter virus was derived from a
pNL4-3 backbone, and the Nef gene replaced the luciferase gene. The NL4-3 lucmCherry virus was a gift
from Warner Greene (12). HIV-1 BaL-3 virus, contributed by Bryan R. Cullen (60), was obtained from the
AIDS Reagent Program. The NL4-3 lucmCherry and BaL-3 viruses have all HIV genes intact, including the
Nef gene. Plasmids containing cyclin L2 constructs were used to transfect 293T cells and HeLa cells using
a Polyplus jetPRIME kit according to the manufacturer’s protocol. For siRNA knockdown of DYRK1A in
293T, HeLa, and THP-1 cells and MDMs, cells were transfected by nucleoporation using Lonza Nucleo-
fector according to the manufacturer’s protocol (61). After transfection, the cells were incubated for 48
h before infection with HIV-1Luc.
Immunofluorescence. HeLa cells expressing green fluorescent protein (GFP)-DYRK1A cultured on
coverslips were rinsed once with phosphate-buffered saline (PBS), fixed for 10 min with 4% paraformal-
dehyde, then washed twice with 1 PBS, and permeabilized with 0.1% Triton X-100. Fixed cells were
then blocked with 1% BSA in 1 PBS-Tween (PBST) at room temperature for 30 min, followed by
overnight incubation with primary antibodies at 4°C. They were then washed with 1 PBST and
incubated at room temperature for 1 h with Alexa Fluor secondary antibody. Control coverslips were
prepared without primary antibodies. Images were taken and processed on a confocal fluorescence
microscope.
Cell lines, virus production, and infections. Small hairpin RNA (shRNA) virus particles were
obtained by cotransfecting 293Tcells using Lipofectamine 3000 reagent according to the manufacturer’s
protocol (Life Technologies) with pLKO.puro vector containing DYRK1A cocktail shRNA, Gag-Pol, and
vesicular stomatitis virus G protein (VSV-G) at a ratio of 10:2:1.
TtRMPVIR plasmids containing cyclin L2 WT, cyclin L2 P369, and cyclin L2 P330 were cotransfected
in 293T cells with Gag-Pol and VSV-G plasmid at a ratio of 10:2:1. The viral particles were collected as
supernatants 24 to 48 h posttransfection. Cleared supernatants were then used to transduce THP-1 cells
to obtain stable cell lines for DYRK1A shRNA by puromycin selection, and cyclin L2 by GFP fluorescence
activated sorting. HIV-BaL, HIV NL4-3, and HIV-1Luc were produced in 293T cells for 48 h and obtained
as supernatants after transfection with Lipofectamine 3000 reagent according to the manufacturer’s
protocol. Infection of 293T, HeLa, and THP-1 cells and MDMs was achieved by addition of 10 to 100 ng
of p24 of virus to the cells in a 6- or 12-well plate depending on the cell type and the experiment.
Differentiated THP-1 cells and monocyte-derived macrophages required higher concentrations of the
virus. Cells were transduced for 6 h, washed once with PBS, and incubated further for 24 to 48 h. Firefly
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luciferase activity normalized to total protein concentration per well was then measured to assess viral
replication postinfection. Reads of 300 U were considered background.
Immunoprecipitations and Western blotting. Twenty-four to 48 h posttransfection, cells were
washed once with PBS and lysed with PBS buffer with 0.2% NP-40 and protease inhibitor cocktail (Roche).
Total protein was measured with a bicinchoninic acid (BCA) protein assay kit. For immunoprecipitation
assays, supernatants were incubated with immunoprecipitating antibody overnight at 4°C. Protein A-
agarose beads were then used to capture the complexes for 2 h at room temperature or overnight at 4°C,
followed by three washes with PBS– 0.1% NP-40. Immunoprecipitants were eluted with SDS sample
buffer at 100°C for 5 min. Protein samples were separated on a 12.5% SDS-PAGE gel and transferred to
nitrocellulose. The membrane was blocked for 1 h at room temperature or overnight at 4°C in 5% milk
or 4% BSA in PBS– 0.05% Tween 20, followed by incubation with primary antibodies overnight at 4°C. The
membrane was washed with PBS– 0.05% Tween and probed with horseradish peroxidase (HRP)-
conjugated secondary antibodies at room temperature for 1 h. The membranes were stained with
Immobilon Western chemiluminescent HRP (Millipore) or Femto SuperSignal, and quantitation was
processed with ImageJ software.
Statistics. Student’s t test was used for pairwise comparisons and one-way analysis of variance
(ANOVA) with a follow-up Tukey multiple-comparison test for multiple comparisons. P values of 0.05
were considered significant. GraphPad Prism 9.00 software (GraphPad Software, Inc., La Jolla, CA) was
used for calculations.
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